The Impact of Pre-Implant Illness Severity on the Outcomes of Pediatric Patients Undergoing Durable Ventricular Assist Device
We describe the association between illness severity and outcomes in this population.
Although extracorporeal life support (ECLS) is an effective treatment for a heart failure patient with cardiogenic shock, ECLS is typically replaced by a durable left ventricular assist device (LVAD) for a bridge to heart transplantation (HT). Because a durable LVAD is still not available in many countries including Korea, ECLS is continued until HT to investigate the impact of ECLS as a bridge to HT on survival after surgery, we reviewed our experience.
Mechanical circulatory support systems for cardiogenic shock and heart failure are associated with ischemic strokes and intracranial hemorrhages. Impella is a percutaneously placed, ventricular assist device for short-term cardiac support. We aimed to study the prevalence of acute neurologic complications during short-term support with Impella.
Cardiogenic shock remains a complex global health entity associated with high mortality despite increased utilization and availability of acute mechanical circulatory support (AMCS) as a bridge to replacement, recovery and/or palliation. We sought to determine the disease trajectory of patients with chronic heart failure complicated with cardiogenic shock and the impact of surrogates related to clinical severity and impaired hemometabolic status.
PIONEER-HF established the safety of the angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril-valsartan (S/V), in patients hospitalized with acute decompensated heart failure after achieving hemodynamic stability. We have previously shown that transitioning patients in cardiogenic shock directly from intravenous (IV) vasoactive (i.e. vasodilators or inotropes) drugs to S/V can be done safely with tolerance to one-month follow-up. Here we further characterize the hemodynamic impact of S/V after patients have been optimized on vasoactive therapy.
Cardiac power index (CPI) has been used as a predictor of outcomes in cardiogenic shock. Cardiac power efficiency (CPE), which is the CPI divided by the PCWP, has been used successfully to predict response to a durable counterpulsation MCS device. The aim of this study is to evaluate the utility of CPE in predicting outcomes in advanced heart failure patients presenting with decompensation.
The objective of this study is to evaluate the differences in outcomes depending on which form of mechanical support was used.
The objective of this study is to evaluate the use of these temporary support devices in patients with refractory cardiogenic shock.
Data on mechanical circulatory support (MCS) in patients with cardiogenic shock (CS) due to end-stage heart failure (ESHF) are limited. We hypothesised that earlier intervention with MCS in patients with CS due to ESHF at INTERMACS class 2 compared to INTERMACS 1 is associated with less organ dysfunction and better survival .
Right heart failure (RHF) is a severe complication of myocardial infarction (MI). For critical patients in cardiogenic shock after MI temporary circulatory support (TCS) is necessary to provide sufficient cardiac output. The ProtekDuo ® dual-lumen cannula provides a minimally invasive option for TCS, with the TandemHeart® pump or a CentriMag™ assist device. Here, we present the first results with the ProtekDuo® cannula in the setting of acute MI with subsequent RHF as temporary right ventricular assist device (t-RVAD).
In patients with severe biventricular heart failure (HF) and cardiogenic shock, use of biventricular assist device (BVAD) can be a treatment of choice. We are developing an advanced ventricular assist device (AVAD) intended to serve as universal pump for left and/or right heart failure (Fig.1 A,B). The purpose of this initial in silico simulation study was to demonstrate that AVAD design can be suitable for biventricular support.